Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CLPT logo CLPT
Upturn stock ratingUpturn stock rating
CLPT logo

Clearpoint Neuro Inc (CLPT)

Upturn stock ratingUpturn stock rating
$11.7
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

07/03/2025: CLPT (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

2 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $29

1 Year Target Price $29

Analysts Price Target For last 52 week
$29 Target price
52w Low $5.39
Current$11.7
52w High $19.22

Analysis of Past Performance

Type Stock
Historic Profit -52.93%
Avg. Invested days 24
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 07/03/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 330.70M USD
Price to earnings Ratio -
1Y Target Price 29
Price to earnings Ratio -
1Y Target Price 29
Volume (30-day avg) 2
Beta 0.94
52 Weeks Range 5.39 - 19.22
Updated Date 07/5/2025
52 Weeks Range 5.39 - 19.22
Updated Date 07/5/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.76

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -64.51%
Operating Margin (TTM) -72.63%

Management Effectiveness

Return on Assets (TTM) -32.39%
Return on Equity (TTM) -76.21%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 321751523
Price to Sales(TTM) 10.26
Enterprise Value 321751523
Price to Sales(TTM) 10.26
Enterprise Value to Revenue 9.98
Enterprise Value to EBITDA -7.07
Shares Outstanding 28265000
Shares Floating 25400194
Shares Outstanding 28265000
Shares Floating 25400194
Percent Insiders 8.25
Percent Institutions 34.74

ai summary icon Upturn AI SWOT

Clearpoint Neuro Inc

stock logo

Company Overview

overview logo History and Background

ClearPoint Neuro, Inc. was founded in 1998 as MRI Interventions, Inc. It initially focused on developing MRI-guided neurosurgical devices and has evolved into a company offering a platform for delivering drugs and gene therapies into the brain. The company's name changed to ClearPoint Neuro in 2019 to reflect its broader focus.

business area logo Core Business Areas

  • Therapeutic Delivery: ClearPoint's flagship product is its neuro-navigation system used for delivering drugs, gene therapies, and other biologics directly into the brain. This includes the SmartFrame system and related navigation software.
  • Neuro Navigation: Development and marketing of systems used for neurosurgery, providing a more precise, minimally invasive method for accessing targets in the brain.
  • Biologics and Drug Development: Partnerships with pharmaceutical and biotech companies looking to deliver therapies across the blood-brain barrier for various neurological disorders.

leadership logo Leadership and Structure

Joe Burnett is the President and CEO. The company has a standard corporate structure with functional departments such as R&D, Sales and Marketing, Operations, and Finance.

Top Products and Market Share

overview logo Key Offerings

  • ClearPoint System: A neuro-navigation system for delivering drugs and gene therapies to the brain. The competitors are Medtronic, Monteris Medical. Clearpoint's market share information is not publicly available.
  • SmartFrame: A key component of the ClearPoint System that enables real-time MRI guidance during procedures. The competitors are Medtronic, Monteris Medical. Clearpoint's market share information is not publicly available.

Market Dynamics

industry overview logo Industry Overview

The industry involves developing and providing minimally invasive neurosurgical technologies. There is a growing demand for targeted drug delivery and gene therapy techniques in treating neurological disorders.

Positioning

ClearPoint Neuro is positioned as a leader in MRI-guided neurosurgical solutions. Its competitive advantage lies in its real-time MRI guidance and its focus on delivering therapies across the blood-brain barrier.

Total Addressable Market (TAM)

The total addressable market for targeted drug delivery to the brain is estimated to be in the billions of dollars. ClearPoint is well-positioned to capture a significant portion of this TAM through its established platform and strategic partnerships.

Upturn SWOT Analysis

Strengths

  • Proprietary neuro-navigation technology
  • Strong partnerships with pharmaceutical and biotech companies
  • First-mover advantage in MRI-guided drug delivery
  • Minimally invasive procedures
  • Experienced leadership team

Weaknesses

  • Limited revenue compared to larger medical device companies
  • Dependence on partnerships for drug development
  • Requires specialized MRI equipment for use
  • High cost of initial setup

Opportunities

  • Expansion of gene therapy applications
  • Increased adoption of minimally invasive neurosurgery
  • Further partnerships with pharmaceutical companies
  • Development of new delivery methods and devices
  • Geographic expansion into new markets

Threats

  • Competition from larger medical device companies (Medtronic, Monteris)
  • Regulatory hurdles for new drug delivery technologies
  • Reimbursement challenges from healthcare providers
  • Potential for technological obsolescence
  • Economic downturn affecting healthcare spending

Competitors and Market Share

competitor logo Key Competitors

  • MDT
  • MRIC

Competitive Landscape

ClearPoint Neuro's competitive advantage lies in its focus on MRI-guided drug delivery and its strong partnerships with pharmaceutical companies. However, it faces competition from larger medical device companies with greater resources and established market presence.

Growth Trajectory and Initiatives

Historical Growth: ClearPoint Neuro has experienced revenue growth in recent years, driven by increased adoption of its technology and expansion of its partnerships.

Future Projections: Analysts project continued revenue growth for ClearPoint Neuro, driven by the expanding market for gene therapies and the company's strategic partnerships.

Recent Initiatives: Recent strategic initiatives include expanding partnerships with pharmaceutical companies, investing in R&D to develop new delivery methods, and expanding commercial operations.

Summary

ClearPoint Neuro is a growing company positioned well in the neuro-navigation and targeted drug delivery market, driven by innovation and strategic partnerships. While facing competition and lacking profitability, the company is investing in research and development and expanding its commercial reach to benefit from a growing sector. The company must continue to enhance innovation and strengthen market position to achieve sustained success. Keep an eye on R&D costs and revenue increases.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Filings
  • Analyst Reports
  • Industry Publications
  • Company Website

Disclaimers:

The information provided is for informational purposes only and does not constitute financial advice. Market share data are estimates based on available information and may not be precise. Financial data is subject to change.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Clearpoint Neuro Inc

Exchange NASDAQ
Headquaters Solana Beach, CA, United States
IPO Launch date 2020-02-12
President, CEO & Director Mr. Joseph Michael Burnett
Sector Healthcare
Industry Medical Devices
Full time employees 115
Full time employees 115

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V.; UCB Biopharma SRL; NE Scientific, LLC; and University of California, San Francisco, and Johns Hopkins University. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.